
NeuroPace (NASDAQ:NPCE) raised its 2026 revenue outlook after reporting first-quarter results that management said reflected continued demand for its RNS System and improving commercial execution across epilepsy treatment centers.
The company reported total revenue of $22.1 million for the first quarter of 2026. Excluding DIXI Medical, revenue was $22 million, with RNS System revenue of $21.7 million. Chief Financial Officer Patrick Williams said non-GAAP revenue excluding DIXI Medical rose 20.1% from $18.3 million in the prior-year quarter, while RNS System revenue increased 19.5% from $18.2 million in the first quarter of 2025.